Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 3/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | PARP1 | P09874 | 2/20 | 0.30 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.30 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.30 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6075300 | 0.75 | PDK4 (0.30) | PDK4 | |
| SCHEMBL30796599 | 0.72 | PDK4 (0.61) | MAPK1PDK4 | |
| SCHEMBL26954332 | 0.72 | PDK4 (0.61) | MAPK1PDK4 | |
| SCHEMBL6829492 | 0.70 | F2 (0.35) | BRD4CREBBP | |
| SCHEMBL7261773 | 0.70 | CYP11B1 (0.38) | MAPK1 | |
| SCHEMBL6647089 | 0.69 | MIF (0.34) | CREBBP | |
| SCHEMBL6824480 | 0.69 | KDM4E (0.38) | — | |
| SCHEMBL8551150 | 0.69 | NR1H2 (0.33) | — | |
| SCHEMBL3657554 | 0.68 | F2 (0.33) | — | |
| SCHEMBL7527330 | 0.68 | MAPT (0.41) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4536656-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2023239750-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |